Clinical Trial Update: Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy [Phase 4]

View source ↗

Summary

Phase 4 trial comparing palbociclib plus letrozole with standard neoadjuvant chemotherapy regimens for breast cancer is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DOCETAXEL (DOCETAXEL)
• Epirubicin (epirubicin)
• Letrozole (letrozole)
• Palbociclib (palbociclib)

Snippet

Sponsor: Shengjing Hospital | Conditions: Breast Cancer | Phase 4 | Status: NOT_YET_RECRUITING